US 9,429,581 B2Granted

IP-10 antibody dosage escalation regimens

AssigneeBristol-Myers Squibb Company

InventorsAllison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

In certain embodiments, the present invention provides a method of treating an Interferon gamma inducible protein 10 (IP-10)-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.

Claims13

Dependent claims

An isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-Interferon gamma inducible protein 10 (IP-10) antibody MDX-1100 and comprises:

(a) a heavy chain variable region CDR1 comprising SEQ ID NO:
13;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO:
14;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO:
15;
(d) a light chain variable region CDR1 comprising SEQ ID NO:
18;
(e) a light chain variable region CDR2 comprising SEQ ID NO:
19;
and
(f) a light chain variable region CDR3 comprising SEQ ID NO:
20;
(a) a heavy chain variable region CDR1 comprising SEQ ID NO:
23;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO:
24;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO:
25;
(d) a light chain variable region CDR1 comprising SEQ ID NO:
28;
(e) a light chain variable region CDR2 comprising SEQ ID NO:
29;
and
(f) a light chain variable region CDR3 comprising SEQ ID NO:
30;
(a) a heavy chain variable region CDR1 comprising SEQ ID NO:
33;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO:
34;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO:
35;
(d) a light chain variable region CDR1 comprising SEQ ID NO:
38;
(e) a light chain variable region CDR2 comprising SEQ ID NO:
39;
and
(f) a light chain variable region CDR3 comprising SEQ ID NO:
40;
or
(a) a heavy chain variable region CDR1 comprising SEQ ID NO:
43;
(b) a heavy chain variable region CDR2 comprising SEQ ID NO:
44;
(c) a heavy chain variable region CDR3 comprising SEQ ID NO:
45;
(d) a light chain variable region CDR1 comprising SEQ ID NO:
48;
(e) a light chain variable region CDR2 comprising SEQ ID NO:
49;
and
(f) a light chain variable region CDR3 comprising SEQ ID NO:
50.

50 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/055,238Filed 16 Oct 2013 · continuation in part
Priority: 29 Apr 2011
Published: US 2014/0127229 A18 May 2014
Granted: 30 Aug 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

G01N 33/686
Immunoglobulins: anti-idiotype
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…

Family

Application61/480,938Us provisional application · filed 29 Apr 2011
PCT/US2012/035457Parent of this continuation-in-part · filed 27 Apr 2012
Application61/714,402Us provisional application · filed 16 Oct 2012
US 2014/0127229 A1Pre-grant publication · published 8 May 2014
US 9,429,581 B2This patent

From the US filing history. Foreign family members aren’t listed.